---
layout: post
title: "Controlled Correspondence Related to Generic Drug Development; Draft Guidance for Industry; Availability"
date: 2026-02-05 19:01:58 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2022-27827
original_published: 2022-12-22 00:00:00 +0000
significance: 8.00
---

# Controlled Correspondence Related to Generic Drug Development; Draft Guidance for Industry; Availability

**Published:** February 05, 2026 19:01 UTC
**Source:** Federal Register
**Original Published:** December 22, 2022 00:00 UTC
**Document Number:** 2022-27827

## Summary

The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "Controlled Correspondence Related to Generic Drug Development." This guidance provides information regarding the process by which generic drug manufacturers and related industry can submit controlled correspondence to FDA requesting information related to generic drug development and the Agency's process for providing communications related to such correspondence. This guidance also describes the process by which generic drug manufacturers and related industry can submit requests to clarify ambiguities in FDA's controlled correspondence response and the Agency's process for responding to those requests. This draft guidance revises the guidance for industry entitled "Controlled Correspondence Related to Generic Drug Development" issued in December 2020.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2022/12/22/2022-27827/controlled-correspondence-related-to-generic-drug-development-draft-guidance-for-industry)
- API: https://www.federalregister.gov/api/v1/documents/2022-27827

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
